Low testing rates and high BRCA prevalence: Poly (ADP-ribose) polymerase inhibitor use in Middle East BRCA/homologous recombination deficiency-positive cancer patients

Figure 2 Breast and ovarian cancer distribution based on mutation status and ethnicity. A higher percentage of breast cancer (n = 57), both germline BRCA (gBRCA)-positive and gBRCA-negative, was found in Middle Eastern patients excluding United Arab Emirates nationals. Conversely, a higher percentage of ovarian cancer (n = 25), both homologous recombination deficiency HRD-positive and HRD-negative, was found in Asian patients.